Baker Bros. Advisors LP Crispr Therapeutics Ag Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Baker Bros. Advisors LP holds 843,075 shares of CRSP stock, worth $34.3 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
843,075
Previous 100,000
743.08%
Holding current value
$34.3 Million
Previous $5.4 Million
633.49%
% of portfolio
0.42%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding CRSP
# of Institutions
490Shares Held
58MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$323 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$305 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$122 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$121 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$121 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.18B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....